Jones Financial Companies
IMRX icon

Jones Financial Companies’s Immuneering IMRX Stock Holding History

Jones Financial Companies’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$143 Hold
30
– – ﹤0.01% 4871
2026
Q1 		$149 Hold
30
– – ﹤0.01% 4615
2025
Q4 		$197 Buy
+30
New +$193 ﹤0.01% 4270

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Jones Financial Companies's IMRX Position: Q2 2026 in Review

Jones Financial Companies held its Immuneering (IMRX) position steady in Q2 2026 at 30 shares worth $143. The position accounts for ﹤0.01% of the portfolio, ranked #4871.

Jones Financial Companies first reported a position in IMRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $197 in Q4 2025. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Jones Financial Companies held 30 shares of Immuneering worth $143 as of Q2 2026.
  • Jones Financial Companies left its Immuneering share count unchanged in Q2 2026.
  • Immuneering made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #4871 holding.
  • Jones Financial Companies first reported a position in Immuneering in Q4 2025 and has held it in 3 quarters since.
  • Jones Financial Companies's Immuneering position peaked at $197 in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.